1. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma
- Author
-
Joseph Gamboa, Javier Corral, M. Nawar Hakim, Jesus Diaz, Alexander Philipovskiy, Onyedika Umeanaeto, and Sumit Gaur
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Antineoplastic Agents ,Intensive chemotherapy ,Maintenance Chemotherapy ,Bortezomib ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,Positron Emission Tomography Computed Tomography ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,medicine ,Humans ,Maintenance phase ,Lenalidomide ,Chemotherapy ,business.industry ,Disease Management ,Induction Chemotherapy ,General Medicine ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Regimen ,Novel agents ,030220 oncology & carcinogenesis ,Plasmablastic Lymphoma ,Female ,Tomography, X-Ray Computed ,business ,Plasmablastic lymphoma ,medicine.drug - Abstract
Incorporating bortezomib and/or lenalidomide in the management of plasmablastic lymphoma is an attractive option due to the reported high response rates. However, concerns about overlapping toxicities can deter clinicians from incorporating these novel agents into chemotherapy. In this case report we describe a patient with plasmablastic lymphoma, who received both lenalidomide and bortezomib as part of upfront treatment for a high-risk plasmablastic lymphoma. After completing intensive chemotherapy, the patient was transitioned to a regimen of daily lenalidomide and biweekly bortezomib to decrease the chance of relapse. This maintenance phase was given for 6 months and was well tolerated. Despite having multiple adverse risk factors, the patient remains in remission, 18 months following diagnosis.
- Published
- 2019
- Full Text
- View/download PDF